EU regulator says Johnson & Johnson vaccine benefits outweigh risks, shipments to resume in Europe

Johnson & Johnson is set to resume shipments of its COVID-19 vaccine in Europe as the pause in the U.S. continues.
The European Medicines Agency on Tuesday said that "unusual blood clots" should be "listed as very rare side effects" of Johnson and Johnson's COVID-19 vaccine, but it determined the vaccine's benefits "outweigh the risks of side effects," Axios and The New York Times report.
The agency, after reviewing eight cases of rare blood clots among the millions of people in the United States who received the Johnson & Johnson vaccine, found a "possible link" between the vaccine and the blood clots, but it said the "risk of having this side effect is very low."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"Healthcare professionals and people who will receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination," the agency also said.
U.S. health officials last week called for a pause of the Johnson & Johnson vaccine while they examined these rare blood clotting cases. Johnson & Johnson says it will now resume shipment of its vaccine in the European Union, Norway, and Iceland. Meanwhile, the Times notes that an expert panel advising the Centers for Disease Control and Prevention on the Johnson & Johnson vaccine is set to meet later this week, and Dr. Anthony Fauci has predicted the vaccine's pause won't extend beyond this Friday.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Today's political cartoons - March 8, 2025
Cartoons Saturday's cartoons - trade wars, healthcare costs, and more
By The Week US Published
-
Marbled tea eggs recipe
The Week Recommends With a beautiful exterior, these eggs are also marked by their soft yolk
By The Week UK Published
-
The Washington Post: kowtowing to Trump?
Talking Point The newspaper's opinion editor has handed in his notice following edict from Jeff Bezos
By The Week UK Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published